

Improving Access to Home-based Palliative Care for Patients with Advanced Chronic Illness



champ-program.org

COLLABORATION FOR HOME CARE ADVANCES IN MANAGEMENT AND PRACTICE



This presentation was delivered by Miriam Ryvicker, Research Associate and Penny H. Feldman, Director, Center for Home Care Policy & Research of the VNSNY at the 2009 Academy Health Annual Research Meeting, Chicago, IL, June 30th, 2009

CHAMP Activities are possible with generous support from The Atlantic Philanthropies and The John A. Hartford Foundation

Project Team

Penny H. Feldman, P.I.

Project Team

Miriam Ryvicker, Research Associate/ Project Manager
Jennifer Mongoven, Project Manager
Beth Costello, Research Analyst
Evie Andreopoulos, Statistical Analyst

Steering Committee

Mary Jo Vetter, Co-Director
Jeanne Dennis, Co-Director
Marian Haas, Co-Director
Marilyn Liota, Regional Administrator, VNSNY Queens

Clinical Staff

Geraldine Abbatiello, Advanced Illness Management APN
Karol DiBello, Advanced Illness Management APN

Funding: New York State Health Foundation



Problem and Opportunity

- ***Problem:*** Intense, acute care in advanced stages of illness –
 - Does not necessarily = better quality of life or reduced morbidity
 - Does = high Medicare costs, potential misallocation of resources
 - 2000-03: Medicare Spending last 6 months of life (Dartmouth Atlas 2006)
 - U.S. Hospital days per Medicare enrollee . = 11.7 days
 - (NYS = 16.9 days; more than any other state save Hawaii)
 - U.S. Hospice use rate = 27% (NYS = 18.7%)
 - 2001-05 Medicare spending on chronically ill decedents, last two years of life (Dartmouth Atlas 2008)
 - All U.S. Hospital Regions = \$46,412 (NY: Manhattan & Bronx = \$81,143)
- ***Opportunity:*** Proactively manage advanced illness; promote palliative/hospice care use and avoid inappropriate acute care

Evidence and Challenge

- ***Evidence:***
 - Benefits of hospice/palliative care well documented (Casarett, et al., 2005; MedPAC, 2009; Teno and Connor, 2009)
 - Many terminally ill patients enter hospice only in final days before death or not at all (MedPAC 2009)
 - Multiple barriers impede hospice/palliative care use:
 - Unpredictability of death
 - Provider/patient/family attitudes toward death and dying
 - Clinician training
 - Poor communication
 - Regulatory standards and quality measures
 - Third party coverage and reimbursement
- ***Challenge:*** Where and how to situate palliative care to improve patient care & QoL, reduce inappropriate, high-cost resource use

Advanced Illness Management (AIM) Project: Multifaceted Intervention


Goal: Improve access to cost-effective home-based palliative care for home health patients with advanced illness; keep patients at home

Intervention:

- Integrate advanced illness management into care delivery
 - Deploy APN, MD, SW to direct, guide and support
 - Designate/train AIM Clinical Resource Nurse (CRN) for each service team
 - Increase awareness, skills of all team members
 - Develop collaboration between CRN, primary nurse, patient/family
- Identify patients thru “risk” algorithm
- Prepare/implement collaborative, individualized AIM plans: advance care directives, ED alternatives, palliative care, hospice referral
- Develop staff: career path, training, mentoring



AIM MODEL



* Roles of Team Members

- Frontline service manager addresses CRN assignment and caseload issues
- CRN collaborates with primary nurse on AIM plan of care
- Primary nurse follows up with patient, family, and primary care physician on AIM plan of care
- Social workers, therapists, and aides provide additional support to patients as needed

Setting

U.S. Home Health Care – post-acute & long-term care

- ~8000 Medicare-certified HHAs (3 million discharges in 2005)
- Older persons: 85% of home care episodes; multiple chronic conditions; multiple medications; frailty; cognitive impairment
- Over 7% admitted with a serious condition that could result in death within a year. (Murtaugh, unpublished data)
- Dispersed, generalist nursing workforce (few APNs, little geriatric or palliative care training)

VNSNY – Established 1893

- Largest nonprofit home care organization in U.S. – Serves NYC metropolitan area ~31,000 average daily census; ~120,000 patients annually, ~86 service delivery teams, ~2500 nurses, ~650 therapists, ~650 social workers, ~6000 aides
- **Queens region:** 11 teams; 2771 avg. daily census; 232 nurses



Prospective Study Design – Randomization at Team Level

Service Teams: 8 service teams randomized to AIM or usual care status (ninth team serving Chinese/Korean-speaking patients purposively assigned to intervention status)

- ***Patient Population:*** Patients in advanced stages of chronic illness receiving traditional homecare services
- ***Study period:*** 12 months
- ***Evaluation:*** Assessment of the impact of AIM on –
 - Patients:
 - Symptom control, quality of life, care involvement
 - Advance care plans/directives
 - Hospice referral and admission
 - Emergency care & hospital admission
- Nurses' awareness of palliative care
- **Today's presentation focuses on patient outcomes**

Hypotheses

Relative to usual care, AIM team patients will have:

- Better symptom control (pain and dyspnea)
- More involvement in advance care planning & higher rate of Advance Directives (ADs)
- Increased hospice referrals
- Fewer hospital admissions and ED visits

AIM intervention will be cost effective relative to usual care

Methods

Data Sources & Measures

Data sources

- **OASIS:** baseline diagnoses, symptom severity, ADLs/IADLs, informal care, etc.
- **Medications database:** baseline number of medications
- **Administrative data:** baseline demographics, payer, referral source; hospice referral/admission; cumulative home health LOS; home health service use; referral to/admission to hospice; admission to hospital; other discharge
- **In-person patient & nurse surveys –**
 - Patients: cross-sectional “blinded” survey administered 8-12 weeks after study entry: involvement in care, symptoms, advance directives, hospital/ER use
 - Nurses: cross-sectional survey of nurses on intervention and control teams

Measures –

- **Predictor variable –** intervention status (treatment/control)
- **Dependent variables:** self-reported care involvement, pain rating, shortness of breath; service use – home health LOS, no of visits/week by discipline; hospice referrals & admissions; hospital admissions; ER visits
- **Baseline control variables:** team, age, sex, race/ethnicity, language, living alone, referral source, payer, regimen change, poor prognosis, pain and shortness of breath, diagnosis of cancer and COPD, other clinical items



Analytic Methods

Multivariate statistical analysis

▪ *Intent-to-Treat:*

- Include all AIM-eligible patients assigned to intervention and control teams

▪ *Analytic Approach:*

- Adjust for case-mix differences in demographics, function and clinical status
- Adjust for team clustering
- Test AIM's impact on dependent variables

▪ *Multivariate Models:*

- Logistic (hospice admission/referral, any hospitalization, ER use, home care use: nursing, PT, social work, HHA)
- Linear (survey data)
- Survival (time to hospitalization)

▪ *Supplemental Analyses (not reported here)*

- Comparison to AIM-eligible patients outside Queens
- Propensity Score match of patients with documented administration of special AIM assessment tool to similar patients outside Queens



Eligibility Criteria

Patients must meet 1 of the following 3 criteria:

- A. Life expectancy < 6 months AND either poor overall prognosis or poor rehabilitation prognosis

OR

- B. Poor prognosis AND a primary diagnosis of one of the following diseases with severity of 3 or greater:

Malignant neoplasm, Heart failure-CHF, Ischemic heart disease, HIV, Renal Failure, Hepatic Failure, COPD, Parkinson's, Multiple Sclerosis, ALS, Huntington's, and Alzheimer's (for Alzheimer's only, severity must be 4)

OR

- C. Primary or secondary diagnosis of one of the diseases listed above with severity of 4



Descriptive Findings: Baseline

- *AIM- eligible patients were clinically complex:*
 - 48% had a life expectancy of less than 6 months
 - Most common primary diagnoses were: (Cancer – 29.5%, COPD – 13.7%, HF – 10.4%)
 - On average, patients had 4.3 comorbidities, took 8 medications, and needed assistance in 10.3 out of 14 ADLs/IADLs
- *Due to randomization at team level, Intervention and Control patients varied significantly on key demographic (e.g., race) & clinical (e.g., prognosis, pain) variables, controlled for in subsequent analyses*



AIM PATIENTS

Baseline Demographic Characteristics

	Control (N=647)	Intervention (N=471)
Age in years, mean (SD)	72.3 (15.0)	73 (15.0)
Female, % (N)	57.5 (N=372)	55.4 (N=261)
Lives Alone, % (N)	21.8 (N=141)	28.7 (N=135)
White, % (N)	51.0 (N=330)	53.1 (N=250)
Black , % (N)	21.2 (N=137)	12.5 (N=59)
Hispanic, % (N)	14.2 (N=92)	19.5 (N=92)
Asian, % (N)	10.7 (N=69)	14.4 (N=68)
Payer - Medicare FFS, % (N)	35.8 (N=230)	38.6 (N=180)
Payer -- Medicaid FFS , % (N)	7.5 (N=48)	4.5 (N=21)
Payer -- Dually Eligible , % (N)	17.1 (N=110)	18.7 (N=87)
Payer -- HMO (Medicare, Medicaid, Commercial), % (N)	37.5 (N=241)	35.8 (N=167)
Referred from Hospital , % (N)	69.7 (N=451)	79.4 (N=374)
Referred from NH or Rehab , % (N)	12.3 (N=80)	11.3 (N=53)
Referred from Community , % (N)	21.5 (N=139)	12.1 (N=57)

Highlighted cells indicate a significant difference between the control and intervention groups.



AIM PATIENTS

Baseline Clinical Characteristics

	Control	Intervention
Life Expectancy Less than 6 Months, % (N)	47.9 (310)	46.5 (N=219)
Poor Prognosis, , % (N)	82.9 (N=524)	90.1 (N=411)
# of Comorbidities (range 0-5), mean (SD)	4.3 (0.9)	4.3 (0.9)
# of Meds at Admission, mean (SD)	8.3 (4.1)	8.6 (4.2)
Recent regimen Change , % (N)	57.2 (N=370)	65.0 (N=306)
# ADL & IADL Assist. Needed (range 0-14), mean (SD)	10.3 (2.7)	10.2 (2.5)
Dyspnea None or mild , % (N)	26.6 (N=172)	21.0 (N=99)
Dyspnea Moderate , % (N)	18.2 (N=118)	31.0 (N=146)
Dyspnea Severe , % (N)	22.9 (N=148)	21.0 (N=99)
Pain Interferes with Daily Activities , % (N)	51.2 (N=331)	57.8 (N=272)
Primary End-Stage Dx with Severity of 3 or Greater, % (N)**		
Cancer , % (N)	28.1 (N=182)	31.4 (N=148)
CHF , % (N)	13.8 (N=89)	13.6 (N=64)
COPD , % (N)	9.1 (N=59)	12.1 (N=57)
Other End-Stage Disease , % (N)	19.2 (N=124)	14.0 (N=66)




Patient Outcomes: Summary of Findings

- AIM had positive effect on symptoms, care involvement & planning:
 - Better pain control (no difference re shortness of breath)
 - Greater likelihood of care involvement
 - Greater discussion of Advanced Directives (ADs)
 - Significantly more documented ADs, health proxies and living wills
- AIM was associated with
 - Significantly higher LOS in home care
 - No significant increase in hospice referrals or admissions
 - No significant reduction in ED use
- AIM patients had significantly higher probability of hospitalization by 90 days; no significant difference in time to hospitalization
- AIM did not significantly affect use or volume of nurse visits; AIM patients were less likely to have physical therapy
- AIM was not a cost effective vehicle for increasing hospice use or reducing hospitalization



Patient Survey Findings⁺

Survey completed by 257 AIM-eligible clients from Queens: Intervention (n=107); Control (n=150)



Pain scale 1-10; other scales 1-5

*+All results case mix adjusted for demographic and clinical characteristics; *p < 0.10; **p < 0.05*

Chart Review for Advance Directives (N=226)

	Control* (N=132)	Intervention* (N=94)	Case Mix Adjusted Odds Ratio	p-value
Documented Health Care Proxy	29.6%	52.1%	2.89	0.0006
Documented Living Will	6.1%	16.0%	3.20	0.0202
Documented Power of Attorney	10.6%	16.0%	1.51	0.3391
Any Documented Advance Directive	31.1%	53.2%	2.88	0.0007
Other End-of-Life Issues Discussed	22.7%	21.3%	0.78	0.4822

**Unadjusted percentages*



Intent-to-Treat Outcomes


	Control* (n=647)	Intervention* (n=471)	Case Mix Adjusted Odds Ratio / Parameter Estimate	p-value
<i>Home Health LOS</i>	47.7 days	55.5 days	6.40	0.0407
<i>Referral to Hospice</i>	20.3%	26.5%	1.30	0.2522
<i>Admission to Hospice</i>	6.3%	8.5%	1.22	0.4514
<i>90 Hospitalization (Any)</i>	27.7%	36.1%	1.40	0.0191
<i>90 Day ED Use (Any)</i>	21.3%	27.4%	1.25	0.2893
<i>Nursing[^]</i>	98.5%	99.8%	ns	ns
<i>Physical Therapy[^]</i>	65.2%	59.4%	0.73	0.0233
<i>Social Work[^]</i>	29.0%	27.7%	0.99	0.9729
<i>Home Health Aide[^]</i>	48.3%	46.4%	0.88	0.5494

**Unadjusted mean and percentages*

[^]Likelihood of at least one Nursing, PT, Social Work or HHA visit



Estimated Survival Graph for Time to 1st Hospitalization by Study Group*



*Adjusted for age, sex, language, race, primary diagnosis, prognosis, life expectancy, pain, dyspnea, referral source, regimen change and living alone

Study Limitations: Methodological

- Imperfect targeting
 - Algorithm based on expert consensus and face validity
- Randomization by team
 - Team Case Mix variation
- Case mix adjustment
 - Potential unmeasured variation – inadequate adjustment for severity among AIM teams
- Right censoring
- Potential contamination – agency wide emphasis on referring “right” patients to “right” program

AIM: Challenges

Systems:

- Reaching “short-stay” patients covered by managed care
- Initiating & implementing individualized AIM plan before patients cycle back to the hospital
- Enlisting the support of families & primary care physicians
- Initiating advance care discussions “upstream” in illness

Resources:

- Achieving “comfort level” among clinicians in discussing AI
- Adjusting productivity standards for Clinical Resource Nurses

Policies:

- Establishing a firm mechanism to pay for APNs
- Addressing “externalities”



Implications

Strategies to promote effective advanced illness management:

Systems:

- Increase collaboration/communication with:
 - Managed care companies to initiate earlier planning & reach short stay patients
 - Hospitals to achieve more stable hospital discharges
 - Physicians to better manage care at home and broach palliative care

Resources:

- Adjust internal productivity standards for Clinical Resource Nurses
- Intensify and extend training/mentoring of CRNs & home care clinicians

Policy:

- Develop a “palliative care” benefit for home care as for nursing homes
- Address financial incentives/externalities

Research:

- Develop and test new targeting algorithm
- Refine and test new/modified advanced illness management interventions
- Test NP-driven “health care home”

